This new publication from Novartis in collaboration with public health and academic researchers in Finland and the US adds to the evidence-base on how narcolepsy might have been triggered in genetically susceptible individuals.

​In November 2014, the Pharmacovigilance Centre of Netherlands (Lareb) provided an updated overview of Dutch cases of narcolepsy reported to have a link to Pandemrix.

This is the first published study where an attempt has been made to understand the possible biological mechanisms behind development of narcolepsy following vaccination with Pandemrix™.

This observational cohort study utilizing electronic health care records covering 5.8 million Swedes confirmed an increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents (<

This is the sixth EU Member State reporting an association between the development of narcolepsy and vaccination with the AS03-adjuvanted influenza A H1N1 (2009) pandemic vaccine Pandemrix.

​In September 2010 Sweden and Finland noted a number of children had developed narcolepsy seemingly in association with having received the pandemic vaccine used almost exclusively in those countries (Pandemrix)

Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 - Final Report of National Narcolepsy Study Steering Committee, Department of Health, Ireland

​A pair of linked papers from Finland concerning the above topic, one epidemiological and the second combining both clinical and epidemiological were published on March 28th in the open access journal, PLoS One.(1,2).